Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Esperion Theraptc (ESPR)

Esperion Theraptc (ESPR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 496,528
  • Shares Outstanding, K 197,035
  • Annual Sales, $ 116,330 K
  • Annual Income, $ -209,250 K
  • EBIT $ 16 M
  • EBITDA $ 18 M
  • 60-Month Beta 0.96
  • Price/Sales 4.18
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 75.29% ( -4.00%)
  • Historical Volatility 70.58%
  • IV Percentile 6%
  • IV Rank 9.73%
  • IV High 393.52% on 09/20/24
  • IV Low 40.97% on 06/13/24
  • Put/Call Vol Ratio 0.11
  • Today's Volume 1,014
  • Volume Avg (30-Day) 1,699
  • Put/Call OI Ratio 0.23
  • Today's Open Interest 103,385
  • Open Int (30-Day) 101,309

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.11
  • Number of Estimates 5
  • High Estimate -0.08
  • Low Estimate -0.17
  • Prior Year -0.50
  • Growth Rate Est. (year over year) +78.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.87 +34.76%
on 11/07/24
2.60 -3.08%
on 11/11/24
+0.39 (+18.31%)
since 10/22/24
3-Month
1.58 +59.49%
on 10/02/24
2.60 -3.08%
on 11/11/24
+0.81 (+47.37%)
since 08/22/24
52-Week
1.16 +117.22%
on 11/28/23
3.40 -25.88%
on 04/08/24
+1.31 (+108.26%)
since 11/22/23

Most Recent Stories

More News
Esperion to Participate in Upcoming Piper Sandler 36th Annual Healthcare Conference

ESPR : 2.52 (+2.02%)
Esperion Reports 36% Reduction in Major Adverse Limb Events for PAD Patients Treated with Bempedoic Acid at AHA 2024

Bempedoic acid reduces major adverse limb events by 36% in PAD patients unable to take statins, according to new analysis.Quiver AI SummaryEsperion announced that an analysis from the CLEAR Outcomes study...

ESPR : 2.52 (+2.02%)
Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024

ESPR : 2.52 (+2.02%)
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

ESPR : 2.52 (+2.02%)
Esperion's Q3 Loss Wider Than Expected, Revenues Rise Y/Y

Esperion Therapeutics, Inc. ESPR incurred a loss of 15 cents per share for the third quarter of 2024, which was wider than the Zacks Consensus Estimate of a loss of 14 cents. The company had incurred a...

FOLD : 9.66 (+1.68%)
ESPR : 2.52 (+2.02%)
CRSP : 47.88 (+3.43%)
LSTA : 2.88 (+1.27%)
Esperion Therapeutics: Q3 Earnings Snapshot

Esperion Therapeutics: Q3 Earnings Snapshot

ESPR : 2.52 (+2.02%)
Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update

ESPR : 2.52 (+2.02%)
Esperion to Participate in Upcoming Jefferies London Healthcare Conference

ESPR : 2.52 (+2.02%)
Esperion Announces a Featured Presentation in the Late Breaker/Featured Science Track and Three Poster Presentations Accepted for the 2024 American Heart Association (AHA) Scientific Sessions

ESPR : 2.52 (+2.02%)
Esperion to Report Third Quarter 2024 Financial Results on November 7

ESPR : 2.52 (+2.02%)

Business Summary

Esperion Therapeutics, Inc. is a pharmaceutical company focused on the development of oral lipid-management treatments for cardiovascular diseases caused by elevated levels of LDL-C (bad cholesterol).

See More

Key Turning Points

3rd Resistance Point 2.65
2nd Resistance Point 2.59
1st Resistance Point 2.56
Last Price 2.52
1st Support Level 2.47
2nd Support Level 2.41
3rd Support Level 2.38

See More

52-Week High 3.40
Fibonacci 61.8% 2.54
Last Price 2.52
Fibonacci 50% 2.28
Fibonacci 38.2% 2.02
52-Week Low 1.16

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar